← Eichor
Study identifier: NCT06681012 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome (IBS) · Irritable Bowel Syndrome of Diarrhea Type (IBS-D)  ·  Sponsor: Devintec Sagl

PhaseNA
Planned participants330
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease, but imposes a significant burden on society, entailing a decrease in patients' Quality of Life (QoL), elevated rates of psychological comorbidities and loss of work productivity, which might be the greatest in subjects with IBS-D, for whom the fear of incontinence in a social situation can be especially debilitating. Moreover, IBS is associated with significant direct and indirect healthcare costs and has a considerable socioeconomic impact on society. Treatment strategy for IBS is usually based on predominant symptoms and their severity, and requires a strong patient-physician relationship, as well as both non-pharmacological and pharmacological approaches. Lifestyle interventions, such as dietary modifications, physical activity and lifestyle adjustments, and stress reduction/psychological therapy represent the most important initial non-pharmacological clinical approach for IBS patients, especially for those with mild disease. First-line pharmacological options for IBS-D include antidiarrheals, mainly loperamide, to control diarrhoea, as well as antispasmodic drugs to relieve IBS symptoms, in particular abdominal pain. Second-line therapies indicated for the treatment of global IBS-D symptoms include rifaximin, 5-Hydroxytryptamine (5-HT)3 recepto…

This description comes directly from the study's public registry record.

Talk to the study team

Maria Dini  ·  +39 3383236335  ·  maria.dini@prineos.com

Daniela Salvati  ·  +39 3334828012  ·  daniela.salvati@prineos.com

Always discuss trial participation with your own doctor first.

Locations (12)

University Hospitals Leuven (UZ Leuven)Leuven, BelgiumRecruiting
Hôpital AvicenneBobigny, FranceRecruiting
CHU de RouenRouen, FranceRecruiting
IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'OrsolaBologna, BO, ItalyRecruiting
IRCCS Ca' Granda Ospedale Maggiore Policlinico FoundationMilan, ItalyRecruiting
AOU Federico II di NapoliNaples, ItalyRecruiting
Azienda Ospedale Università PadovaPadova, ItalyRecruiting
Fondazione IRCCS Policlinico San MatteoPavia, ItalyRecruiting
Azienda Ospedaliero Universitaria Pisana (AOUP)Pisa, ItalyRecruiting
S. Andrea University HospitalRoma, ItalyRecruiting
Hospital Universitario Vall d´HebronBarcelona, SpainRecruiting
Hospital Universitario Ramón y CajalMadrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06681012